GC Pharma completes 2nd-phase test of Covid-19 plasma therapy
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
According to multiple sources from the pharmaceutical industry on Wednesday, GC Pharma has completed registration of patients for the second phase clinical trial for GC5131A, its Covid-19 plasma treatment, as well as injection on Dec. 31.
GC Pharma has developed GC5131A – a therapy that uses blood plasma taken from convalescent donors after Covid-19 infections – and conducted the second phase clinical test on high-risk patients until the end of last year. The clinical trial was conducted at 15 medical sites in Korea.
An unnamed official from GC Pharma said that the company is compiling and analyzing the test data after it finished its injection to 60 patients. It aims to complete the remaining procedure by March and apply for conditional approval for use of the Covid-19 treatment with the Ministry of Food and Drug Safety.
The official noted that GC Pharma recently completed the production of the third batch of the cure, a move that will enable immediate use of the plasma therapy once the ministry gives a nod to its condition use.
The company has collected plasma from 4,126 out of 6,538 individuals who agreed to donate their blood with antibodies after they recovered from Covid-19.
GC Pharma’s plasma therapy for Covid-19 has already been prescribed to patients at medical sites under strict conditions. The therapy has been approved by Korea’s food and drug safety ministry for 30 cases under medical purpose. Since October, the cure has been used at different sites including Kyungpook National University Chilgok Hospital and Soon Chun Hyang University Hospital Bucheon until recently.
Under the country’s patient treatment scheme, a medicine – even if it is under clinical trial phase – can be used for special purpose to treat intensive care patients whose lives are threatened without other treatment options. The medicine can be used only by the hospital that has applied for approval and to the particular patient. The scheme is separate from the overall clinical trial or conditional approval.
GC Pharma shares finished Wednesday at 427,000 won ($393.08), down 3.06 percent from the previous day.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Shares of Hanmi Pharm, GC strong on potential CMO deal for Moderna vaccines - Pulse by Maeil Business News Korea
- Kakao Enterprise bags $92 mn investment from KDB, joins unicorn rank - Pulse by Maeil Business News Korea
- BTS “Dynamite” stays at Billboard singles top 10 longest for K-pop act - Pulse by Maeil Business News Korea
- Korea’s biohealth exports at record high last year, join 10 mainstay rank - Pulse by Maeil Business News Korea
- Korea’s kimchi exports record high in the year of pandemic - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- “BIMO는 문제없어” 자신한 HLB, 시장 반응은 ‘글쎄’ [재계 TALK TALK]
- 홍진호, 결혼 2개월 만에 아빠 되다...“연말에 태어날 우리 콩콩이” (공식) - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이